Teva launches pre-filled pen for anti-CGRP migraine therapy AJOVY®▽ (fremanezumab) in the UK - ACNR | Paper & Online Neurology Journal ACNR | Paper & Online Neurology Journal
Teva Pharmaceutical Industries Ltd. - New research by Teva has thrown a spotlight on how badly affected women are by #migraine. But behind those numbers are real people. Come and meet some
Teva stops selling migraine patches after reports of burns | The Times of Israel
Eli Lilly avoids sanctions in Teva migraine treatment dispute
Teva migraine medicine gets EU positive opinion
Teva - Migraine World Summit
Teva tackles migraine through potential $400m Heptares collaboration
EMA set to review Teva's migraine injection - PMLiVE
Teva Pharmaceuticals on Twitter: "Migraine is not just a headache. Our migraine expert, Dr Joshua Cohen, explains why it's time to break the stigma. #MigraineandHeadacheAwarenessMonth https://t.co/rD3hXiRVoc https://t.co/b46jYhpZSH" / Twitter
Teva's migraine injection approved in Europe - PMLiVE
Showcasing Teva's Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache... | Business
Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed - Ypsomed - Group
Beyond Migraine: Mental health, hormones and exercise discussed in new podcast
Teva discontinues trial of Ajovy for episodic cluster headache - Pharmaceutical Technology
Teva's migraine med given marketing authorization
Beyond Migraine Podcast - Migraine Association of Ireland
Teva's Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine | Pharmafile
U.S. regulator approves Teva migraine drug, shares rise | Reuters
Teva's CGRP-Inhibitor Reduced Monthly Migraine Days in Late-Stage Trial | BioSpace
Teva's migraine prophylaxis drug now approved in Europe
Amgen's Aimovig, under fire from Lilly, loses grip on next-gen migraine share | FiercePharma
No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | FiercePharma
Teva pulls migraine patch Zecuity on reports of burning, scarring | FiercePharma
Ajovy, Teva's migraine drug, recommended by UK's NICE.
Teva hopes to launch migraine drug as soon as September | Reuters
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug | BioSpace
